Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-04-30T16:50:52.495Z Has data issue: false hasContentIssue false

24 - Iron overload associated with congenital dyserythropoietic anemias

Published online by Cambridge University Press:  01 June 2011

James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah Medical Center
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
James C. Barton
Affiliation:
University of Alabama, Birmingham
Corwin Q. Edwards
Affiliation:
University of Utah School of Medicine, Salt Lake City
Pradyumna D. Phatak
Affiliation:
University of Rochester Medical Center, New York
Robert S. Britton
Affiliation:
St Louis University, Missouri
Bruce R. Bacon
Affiliation:
St Louis University, Missouri
Get access

Summary

The term congenital dyserythropoietic anemia (CDA) encompasses a group of rare heritable disorders characterized by anemia, ineffective erythropoiesis, structural and functional abnormalities of erythroblasts and mature erythrocytes, and increased iron absorption. CDA type I is the second most prevalent subtype (OMIM #224120). CDA type II is the most common subtype (OMIM #224100). CDA type II is often described by the acronym HEMPAS (hereditary erythroblastic multinuclearity with positive acidifed serum test). The clinical manifestations of these two subtypes of CDA are reviewed herein with an emphasis on the complication of iron overload.

General characteristics

Characteristics shared by patients with various subtypes of CDA include ease of fatigue, pallor, scleral icterus, jaundice, and splenomegaly. Some patients have abnormal fingernails or toenails, abnormal shapes or size of bones in the feet, or scoliosis. Circulating erythrocytes are often macrocytic and may have abnormal expression of membrane antigens. The bone marrow typically reveals erythroid hyperplasia, CDA erythroblasts are often enlarged, and have abnormal nuclear contours, nuclear fragmentation (karyorrhexis), or multinuclearity. In some patients with CDA, the rate of erythrocyte destruction is increased, resulting in anemia, reticulocytosis, and hyperbilirubinemia.

Congenital dyserythropoietic anemia type I (OMIM #224120)

Clinical manifestations

The median age at diagnosis is about 17 years (range birth to about age 45 years). In a study of 70 Israeli Bedouin patients with CDA type I, 64% had identifiable abnormalities at birth.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wickramasinghe, SN, Wood, WG. Advances in the understanding of the congenital dyserythropoietic anaemias. Br J Haematol 2005; 131: 431–46.CrossRefGoogle ScholarPubMed
Shalev, H, Kapelushnik, J, Moser, A, Dgany, O, Krasnov, T, Tamary, H. A comprehensive study of the neonatal manifestations of congenital dyserythropoietic anemia type I. J Pediatr Hematol Oncol 2004; 26: 746–8.CrossRefGoogle ScholarPubMed
Shalev, H, Kapleushnik, Y, Haeskelzon, L, et al. Clinical and laboratory manifestations of congenital dyserythropoietic anemia type I in young adults. Eur J Haematol 2002; 68: 170–4.CrossRefGoogle ScholarPubMed
Heimpel, H, Schwarz, K, Ebnother, M, et al. Congenital dyserythropoietic anemia type I (CDA I): molecular genetics, clinical appearance, and prognosis based on long-term observation. Blood 2006; 107: 334–40.CrossRefGoogle ScholarPubMed
Tamary, H, Dgany, O, Proust, A, et al. Clinical and molecular variability in congenital dyserythropoietic anaemia type I. Br J Haematol 2005; 130: 628–34.CrossRefGoogle ScholarPubMed
Goede, JS, Benz, R, Fehr, J, Schwarz, K, Heimpel, H. Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy. Ann Hematol 2006; 85: 591.CrossRefGoogle ScholarPubMed
Chrobak, L, Hulek, P, Nozicka, J.[Congenital dyserythropoietic anemia-type II (CDA-II) in three siblings with long-term follow-up and iron overload.]Acta Medica (Hradec Kralove) Suppl 2004; 47: 29–33.Google Scholar
Papanikolaou, G, Tzilianos, M, Christakis, JI, et al. Hepcidin in iron overload disorders. Blood 2005; 105: 4103.CrossRefGoogle ScholarPubMed
Tamary, H, Shalev, H, Perez-Avraham, G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 2008; 112: 5241–4.CrossRefGoogle ScholarPubMed
Fargion, S, Valenti, L, Fracanzani, AL, et al. Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. Blood 2000; 96: 3653.Google Scholar
Noy-Lotan, S, Dgany, O, Lahmi, R, et al. Codanin-1, the protein encoded by the gene mutated in congenital dyserythropoietic anemia type I (CDAN1), is cell cycle-regulated. Haematologica 2009; 94: 629–37.CrossRefGoogle Scholar
Ahmed, MR, Chehal, A, Zahed, L, et al. Linkage and mutational analysis of the CDAN1 gene reveals genetic heterogeneity in congenital dyserythropoietic anemia type I. Blood 2006; 107: 4968–9.CrossRefGoogle ScholarPubMed
Lavabre-Bertrand, T, Ramos, J, Delfour, C, et al. Long-term alpha interferon treatment is effective on anaemia and significantly reduces iron overload in congenital dyserythropoiesis type I. Eur J Haematol 2004; 73: 380–3.CrossRefGoogle ScholarPubMed
Marwaha, RK, Bansal, D, Trehan, A, Garewal, G. Interferon therapy in congenital dyserythropoietic anemia type I/II. Pediatr Hematol Oncol 2005; 22: 133–8.CrossRefGoogle ScholarPubMed
Smithson, WA, Perrault, J. Use of subcutaneous deferoxamine in a child with hemochromatosis associated with congenital dyserythropoietic anemia, type I. Mayo Clin Proc 1982; 57: 322.Google Scholar
Iolascon, A, Delaunay, J, Wickramasinghe, SN, Perrotta, S, Gigante, M, Camaschella, C. Natural history of congenital dyserythropoietic anemia type II. Blood 2001; 98: 1258–60.CrossRefGoogle ScholarPubMed
Heimpel, H, Anselstetter, V, Chrobak, L, et al. Congenital dyserythropoietic anemia type II: epidemiology, clinical appearance, and prognosis based on long-term observation. Blood 2003; 102: 4576–81.CrossRefGoogle ScholarPubMed
Heimpel, H, Wilts, H, Hirschmann, WD, et al. Aplastic crisis as a complication of congenital dyserythropoietic anemia type II. Acta Haematol 2007; 117: 115–18.CrossRefGoogle ScholarPubMed
Steenbergen, W, Matthijs, G, Roskams, T, Fevery, J. Non-iatrogenic haemochromatosis in congenital dyserythropoietic anaemia type II is not related to C282Y and H63D mutations in the HFE gene: report on two brothers. Acta Clin Belg 2002; 57: 79–84.CrossRefGoogle Scholar
Halpern, Z, Rahmani, R, Levo, Y. Severe hemochromatosis: the predominant clinical manifestation of congenital dyserythropoietic anemia type II. Acta Haematol 1985; 74: 178–80.CrossRefGoogle Scholar
Faruqui, S, Abraham, A, Berenfeld, MR, Gabuzda, TG. Normal serum ferritin levels in a patient with HEMPAS syndrome and iron overload. Am J Clin Pathol 1982; 78: 97–101.CrossRefGoogle Scholar
Hovinga, JA, Solenthaler, M, Dufour, JF. Congenital dyserythropoietic anaemia type II (HEMPAS) and haemochromatosis: a report of two cases. Eur J Gastroenterol Hepatol 2003; 15: 1141.CrossRefGoogle Scholar
Chrobak, L. Successful treatment of iron overload with phlebotomies in two siblings with congenital dyserythropoietic anemia type II (CDA-II). Acta Medica (Hradec Kralove) 2006; 49: 193.Google Scholar
Schwarz, K, Iolascon, A, Verissimo, F, et al. Mutations affecting the secretory COPII coat component SEC23B cause congenital dyserythropoietic anemia type II. Nat Genet 2009; 41: 936–40.CrossRefGoogle ScholarPubMed
Vassiliadis, T, Garipidou, V, Perifanis, V, et al. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006; 12: 818–21.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×